Conigen’s GPR52-specific mouse mAb targeting the 44aa N-terminal domain can potently bind the full length human GPR52 expressed on live cells by flow cytometry and the N-terminus antigen by ELISA. GPR52 (UniProt# Q9Y2T5) is an orphan G protein–coupled receptor predominantly expressed in the brain, especially in the striatum, where it is enriched in medium spiny neurons. Unlike many GPCRs, GPR52 exhibits constitutive activity, meaning it can signal in the absence of a known endogenous ligand. Due to its localization and signaling properties, GPR52 has attracted interest as a potential therapeutic target for neuropsychiatric disorders such as schizophrenia and Huntington’s disease. 

Antibodies against GPR52 are available from other suppliers, offered in both polyclonal and monoclonal formats for Western blot, immunohistochemistry, immunofluorescence at denatured or fixed cell conditions. However, antibodies for detection of GPR52 on live cells could not be found from other suppliers. Conigen’s GPR52-specific live cell staining antibody provides an important tool to study GPR52 expression on live cells including primary cells and transfected cells for research and drug discovery, supporting studies of receptor expression, localization, and pharmacological modulation. 

It is activated by endogenous peptide ligands, primarily apelin and ELABELA (also called Toddler), which bind to the receptor and trigger intracellular  pathways. Dysregulation of the apelin–APLNR system has been linked to diseases such as heart failure, hypertension, diabetes, and obesity. Because of its wide physiological relevance, APLNR has emerged as a promising therapeutic target. APLNR antibodies are available in monoclonal, polyclonal, and recombinant formats for applications including Western blot, immunohistochemistry, immunofluorescence and ELISA. 

Very limited antibodies are available for live cell staining by flow cytometry. Selection depends on application, species reactivity, epitope accessibility, and validation data. Conigen’s APLNR-specific live cell staining antibody provides an important tool to study the APLNR target expression on live cells including primary cells and transfected cells for research and drug discovery, supporting studies of receptor expression, localization, and pharmacological modulation.